Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
Date:5/2/2013

therapy in men with metastatic CRPC, and ENSPIRIT will evaluate the potential survival benefit of combining custirsen with docetaxel as second-line chemotherapy in patients with advanced or metastatic NSCLC.

"The initiation of multiple investigator-sponsored Phase 2 trials, across tumor types, represents a significant inflection point in the creation of value for OGX-427 for which we currently retain all commercialization rights," said Scott Cormack , President and Chief Executive Officer, OncoGenex Pharmaceuticals, Inc. "Considered alongside the three Phase 3 trials of custirsen, and a strong cash position that will sustain us into 2015, well past the SYNERGY data read-out, we believe the company is well situated to continue to execute against our development goals."

First Quarter 2013 Financial Update and Results

  • Revenue for the first quarter of 2013 increased to $5.1 million from $1.3 million for the first quarter of 2012. The increase was due to higher revenue earned through the Company's strategic collaboration with Teva, resulting from clinical development activities associated with the AFFINITY trial which was initiated in August 2012.
  • Total operating expenses for the first quarter of 2013 increased to $13.4 million from $6.8 million for the first quarter of 2012. The increase was due primarily to higher clinical trial expenses associated with patient enrollment in the AFFINITY and Borealis-1 trials, increased costs directly associated with efforts to increase patient enrollment and higher employee expenses, including stock based compensation expenses.  These increases were partially offset by lower manufacturing expenses due to timing of OGX-427 manufacturing activities.
  • Net loss for the first quarter of 2013 was $6.7 million, or $0.46 per diluted common share compared with a net loss of $6.9 million, or $0.67 per diluted common share for the first quarter of 2012.  The
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
    2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    3. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    4. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
    6. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
    7. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
    8. Avion Pharmaceuticals, LLC., announces further expansion of their Womens Health Sales Team
    9. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
    10. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
    11. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
    (Date:12/24/2014)... CHENGDU, China, Dec. 24, 2014 /PRNewswire/  -- Tianyin ... a pharmaceutical company that specializes in the patented ... and active pharmaceutical ingredients (API) released unaudited preliminary ... year 2015. Fiscal Year 2015 Ended ... was $9.7 million compared with $14.7 million in ...
    (Date:12/24/2014)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... on December 24, 2014 it closed its previously ... raised approximately $2.3 million in gross proceeds from ... proceeds from the offering to fund its research ...
    Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
    ... Company (Nasdaq: PRGO;TASE) today announced that its Board ... per share, payable on March 20, 2012 to ... Perrigo Company is a leading global healthcare ... generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, ...
    ... Corporation (NASDAQ: LIFE ) today announced ... Leader, GE Molecular Diagnostics, has joined the company as ... of experience in the diagnostics industry, including leadership positions ... As President, Medical Sciences at Life Technologies, ...
    Cached Medicine Technology:Ronnie Andrews Joins Life Technologies as President, Medical Sciences 2Ronnie Andrews Joins Life Technologies as President, Medical Sciences 3Ronnie Andrews Joins Life Technologies as President, Medical Sciences 4
    (Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
    (Date:12/25/2014)... (PRWEB) December 25, 2014 AngelWeddingDress.com tries ... to the online realm. Today, the business has introduced ... a site-wide prom dress promotion. , The new prom ... each and every dress lover. They are specially designed ... 2015 prom dresses should visit its website before ...
    (Date:12/25/2014)... (PRWEB) December 25, 2014 “ SmileStix ” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review and ... to create personal stickers. , The old saying goes, “A ... lot of words that can describe a single image, because ...
    (Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
    (Date:12/25/2014)... Parker & Sons, Inc. an industry leader when ... regarding heating, cooling and plumbing services in the greater ... “Queen of Clean” for impressive contractor services in Arizona. ... the years for providing outstanding quality customer service and ... for both homeowners and businesses. Linda Cobb, known as ...
    Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3
    ... Louis University published his findings on a better substitute ... ,According to peer-reviewed research published in Vaccine this new ... were looking for. ,In its first human ... four sites around the United States, said Geoffrey Gorse, ...
    ... drug designed to treat chronic inflammatory conditions and leukemia ... British men involved in the trail becoming seriously ill. ... the drug reaction. ,Dr. Ganesh Suntharalingam and ... the immune system overreaction, known as a cytokine storm, ...
    ... South Asia's AIDS epidemic would grow rapidly unless eight ... groups with better HIV prevention// measures, according to a ... people are infected with HIV in South Asia, with ... industry and injection drug use, said the report presented ...
    ... Bill Clinton and Microsoft boss Bill Gates said inadequate access ... in combating the AIDS epidemic, in addresses to the largest ... to continue to fight the stigma and stop people from ... ,Both Clinton and Gates have donated billions of ...
    ... Britain, Monday questioned India's Centre for Science and Environment (CSE) ... Cola and said they did not "detect any such residues". ... detected no residues of the pesticides allegedly found in the ... is no proof of accuracy and validation." ,CSL's ...
    ... to encourage fidgeting and other restless behaviors that consume calories ... by The American Physiological Society. ,The study found ... more sensitive to a chemical produced in the brain, orexin ... fidgeting and other unconscious movements. Compared to rats bred to ...
    Cached Medicine News:Health News:Experimental Drug Causes Cytokine Storm 2Health News:India Urged to Take Stringent Measures to Combat AIDS 2Health News:India Urged to Take Stringent Measures to Combat AIDS 3Health News:British Laboratory Certifies Coke as 'Safe' 2Health News:Biological Basis Behind a Couch Potato 2Health News:Biological Basis Behind a Couch Potato 3